We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$791M
1-Year Est. Return
245.83%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$233M
AUM Growth
–
Cap. Flow
+$98.4M
Cap. Flow
% of AUM
42.21%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
107
New
107
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$9.19M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$8.94M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$6.13M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$5.88M |
| 5 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$5.46M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 61.92% |
| 2 | Healthcare | 38.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
AnaptysBio
ANAB
$1.61B
| $2.85M | 1.22% |
+215,000
| New | +$5.21M |
|
27
CALL
Capricor Therapeutics
CAPR
$524M
| $2.76M | 1.18% |
+200,000
| New | +$3.5M |
|
28
CALL
BridgeBio Pharma
BBIO
$13B
| $2.74M | 1.18% |
+100,000
| New | +$2.58M |
|
29
CALL
Celldex Therapeutics
CLDX
$2.97B
| $2.53M | 1.08% |
+100,000
| New | +$2.72M |
|
30
Arcus Biosciences
RCUS
$3.23B
| $2.47M | 1.06% |
+165,965
| New | +$2.71M |
|
31
Scholar Rock
SRRK
$5.67B
| $2.3M | 0.99% |
+53,160
| New | +$1.73M |
|
|
APGE
32
DELISTED
Apogee Therapeutics
APGE
| $2.29M | 0.98% |
+50,620
| New | +$2.58M |
|
|
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.21M | 0.95% |
+131,862
| New | +$2.18M |
|
34
CALL
Ultragenyx Pharmaceutical
RARE
$1.43B
| $2.2M | 0.94% |
+52,300
| New | +$2.59M |
|
35
Relay Therapeutics
RLAY
$4.13B
| $2.08M | 0.89% |
+505,778
| New | +$2.75M |
|
36
CALL
Keros Therapeutics
KROS
$222M
| $2.06M | 0.88% |
+130,000
| New | +$6.76M |
|
37
CALL
Recursion Pharmaceuticals
RXRX
$1.98B
| $2.03M | 0.87% |
+300,000
| New | +$2.02M |
|
|
38
CALL
Scholar Rock
SRRK
$5.67B
| $1.86M | 0.8% |
+43,000
| New | +$1.4M |
|
39
Jazz Pharmaceuticals
JAZZ
$15.7B
| $1.81M | 0.78% |
+14,719
| New | +$1.73M |
|
40
CALL
uniQure
QURE
$3.06B
| $1.77M | 0.76% |
+100,000
| New | +$863K |
|
41
Oric Pharmaceuticals
ORIC
$1.32B
| $1.73M | 0.74% |
+214,291
| New | +$1.97M |
|
42
CALL
Altimmune
ALT
$621M
| $1.44M | 0.62% |
+200,000
| New | +$1.53M |
|
43
TG Therapeutics
TGTX
$8.77B
| $1.44M | 0.62% |
+47,805
| New | +$1.37M |
|
44
Replimune Group
REPL
$1.23B
| $1.38M | 0.59% |
+114,000
| New | +$1.39M |
|
|
CRNX
45
DELISTED
Crinetics Pharmaceuticals
CRNX
| $1.32M | 0.57% |
+25,900
| New | +$1.45M |
|
|
46
PUT
AnaptysBio
ANAB
$1.61B
| $1.32M | 0.57% |
+100,000
| New | +$2.42M |
|
47
VistaGen Therapeutics
VTGN
$10.9M
| $1.31M | 0.56% |
+442,520
| New | +$1.25M |
|
48
Denali Therapeutics
DNLI
$3.16B
| $1.22M | 0.52% |
+60,000
| New | +$1.54M |
|
|
NUVL
49
DELISTED
Nuvalent
NUVL
| $1.15M | 0.49% |
+14,701
| New | +$1.37M |
|
50
Evolus
EOLS
$524M
| $1.08M | 0.46% |
+97,423
| New | +$1.37M |
|
Similar funds
KAS
FSAG
KAS
BSSFA
GUB
EA
BBES
GEA
Diadema Partners's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Diadema Partners, which disclosed 107 positions worth $233M. Its ten largest holdings account for 44% of the portfolio.
Its largest position is AbbVie: 50,000 shares worth $8.88M.
By sector, the portfolio is most concentrated in Miscellaneous at 62% of assets, followed by Healthcare.
- Diadema Partners's largest Q4 2024 buy was AbbVie: 50,000 shares worth $8.88M.
- Diadema Partners's ten largest holdings make up 44% of its $233M portfolio in Q4 2024.
- Diadema Partners disclosed 107 positions in Q4 2024, its first 13F filing on record.
Based on Diadema Partners's 13F filing for Q4 2024, filed 14 Feb 2025.